Evaluation of the clinical characteristics of everolimus-induced lung injury and determination of associated risk factors. (January 2018)
- Record Type:
- Journal Article
- Title:
- Evaluation of the clinical characteristics of everolimus-induced lung injury and determination of associated risk factors. (January 2018)
- Main Title:
- Evaluation of the clinical characteristics of everolimus-induced lung injury and determination of associated risk factors
- Authors:
- Abe, Mitsuhiro
Tsushima, Kenji
Ikari, Jun
Kawata, Naoko
Terada, Jiro
Tanabe, Nobuhiro
Tatsumi, Koichiro - Abstract:
- Abstract: Background: Everolimus (ERL), a mammalian target of rapamycin (mTOR) inhibitor, has been used for the management of several advanced cancers. ERL frequently causes lung injury, although the clinical and radiographic features have not been clarified. The aim of this study was to assess the clinical features of ERL-induced lung injury and determine the associated risk factors. Methods: This single-center, retrospective study included 45 patients (29 men, 16 women; age, 12–78 years) who had received ERL at our hospital between August 2010 and March 2016. Drug-induced lung injury (DILI) was diagnosed using the Japanese Respiratory Society criteria. We obtained information regarding the clinical course, symptoms, clinical findings, blood test findings, and chest computed tomography findings from the patients' medical records. Risk factors for DILI onset were investigated using the Wilcoxon rank sum test. Results: Fifteen patients (33%) were diagnosed with DILI. The median time from ERL administration to DILI onset was 64 days. High Serum Krebs von den Lungen-6 (KL-6) levels and a low estimated glomerular filtration rate (eGFR) before ERL administration were found to be significant risk factors for DILI. KL-6 and lactate dehydrogenase (LDH) were significantly elevated at the onset of DILI. All 15 patients recovered; 11 were without steroids. Conclusions: Our results suggest that patients with high KL-6 levels and a low eGFR at baseline are at increased risk ofAbstract: Background: Everolimus (ERL), a mammalian target of rapamycin (mTOR) inhibitor, has been used for the management of several advanced cancers. ERL frequently causes lung injury, although the clinical and radiographic features have not been clarified. The aim of this study was to assess the clinical features of ERL-induced lung injury and determine the associated risk factors. Methods: This single-center, retrospective study included 45 patients (29 men, 16 women; age, 12–78 years) who had received ERL at our hospital between August 2010 and March 2016. Drug-induced lung injury (DILI) was diagnosed using the Japanese Respiratory Society criteria. We obtained information regarding the clinical course, symptoms, clinical findings, blood test findings, and chest computed tomography findings from the patients' medical records. Risk factors for DILI onset were investigated using the Wilcoxon rank sum test. Results: Fifteen patients (33%) were diagnosed with DILI. The median time from ERL administration to DILI onset was 64 days. High Serum Krebs von den Lungen-6 (KL-6) levels and a low estimated glomerular filtration rate (eGFR) before ERL administration were found to be significant risk factors for DILI. KL-6 and lactate dehydrogenase (LDH) were significantly elevated at the onset of DILI. All 15 patients recovered; 11 were without steroids. Conclusions: Our results suggest that patients with high KL-6 levels and a low eGFR at baseline are at increased risk of ERL-induced lung injury. In addition, KL-6 and LDH may be useful biomarkers of ERL-induced lung injury. Highlights: High KL-6 and low eGFR at baseline are risk factors for ERL-induced lung injury. KL-6 and LDH may be useful biomarkers of ERL-induced lung injury. ERL-induced lung injury may include other than interstitial pneumonia. … (more)
- Is Part Of:
- Respiratory medicine. Volume 134(2018)
- Journal:
- Respiratory medicine
- Issue:
- Volume 134(2018)
- Issue Display:
- Volume 134, Issue 2018 (2018)
- Year:
- 2018
- Volume:
- 134
- Issue:
- 2018
- Issue Sort Value:
- 2018-0134-2018-0000
- Page Start:
- 6
- Page End:
- 11
- Publication Date:
- 2018-01
- Subjects:
- Drug-induced lung injury -- Everolimus -- Mammalian target of rapamycin (mTOR) -- Lactate dehydrogenase -- Krebs von den Lungen-6 -- Ground-glass opacity
Chest -- Diseases -- Periodicals
Chest -- Diseases -- Great Britain -- Periodicals
Respiratory organs -- Diseases -- Periodicals
Respiratory Tract Diseases -- Periodicals
Appareil respiratoire -- Maladies -- Périodiques
Thorax -- Maladies -- Périodiques
Appareil respiratoire -- Maladies -- Traitement -- Périodiques
Electronic journals
616.2 - Journal URLs:
- http://www.sciencedirect.com/science/journal/09546111 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09546111 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09546111 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.rmed.2017.11.009 ↗
- Languages:
- English
- ISSNs:
- 0954-6111
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7777.661900
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 6010.xml